COVID-19 Reactogenicity

Summary

The purpose of this study is to compare post-vaccination reactions between the protein-based Novavax vaccine and the mNEXSPIKE mRNA-1283 vaccine. Specifically, the study aims to determine the rate of participant-reported symptoms associated with each type of vaccine.

Timeline

Start

2025-10-01

Primary completion

2026-06-14

Completion

2026-06-14

Outcome

Met primary endpoint

release “The study met its primary endpoint – the probability of experiencing at least one systemic reaction within seven days of vaccination - with statistical significance” sanofi.com ↗

Drugs

Indications